(Yicai) July 17 -- Sino Biopharmaceutical said the Chinese drugmaker plans to invest no more than USD951 million to fully ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's rules on approving new medicines as well as a row over drug prices.

On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.

Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation ...

In just the past month, AstraZeneca (AZN) signed a drug discovery agreement worth up to $5.3 billion USD with China-based CSPC Pharmaceutical Group to co-develop pre-clinical drug candidates powered ...

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the discovery of novel oral therapies for chronic diseases. The partnership, ...

AstraZeneca is paying China’s CSPC Pharmaceutical $110 million upfront to discover new oral drugs for chronic diseases, including one potential project for immunological diseases. The deal ...

AstraZeneca plc, a British-Swedish multinational pharmaceutical and biotechnology company, has entered into a strategic partnership agreement with China's CSPC Pharmaceuticals Group Limited to develop ...